Latest studies
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo- Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID)
This study looks at a new medicine called benralizumab for adults with severe nose polyps and asthma. It aims to see if it can shrink polyps and reduce stuffy noses better than a dummy treatment, using standard nasal sprays alongside.
Severe CRSwNP patients with asthma.Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744
This study looks at the long-term safety of a new medicine, GSK3511294 (Depemokimab), for adults and teenagers with severe asthma. Participants have already taken part in earlier studies of this medicine. We'll check for side effects and how their asthma is doing over a year.
Severe asthma with an eosinophilic phenotypeHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, double-dummy, multicenter, multinational study to assess the efficacy and safety of orally administered tebipenem pivoxil hydrobromide (TBP-PI-HBr) compared to intravenously (IV) administered imipenem-cilastatin in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)
This study is looking at a new tablet treatment for serious urinary tract infections (UTIs) and kidney infections. It compares this new tablet with a standard IV (into the vein) treatment to see if it's safe and works well.
complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)Hungary - RecruitingPHASE2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
This study is looking into a new medicine called Ianalumab for people in the UK with a specific type of scleroderma called diffuse cutaneous systemic sclerosis. It aims to see if the drug is safe and helps with symptoms, compared to a dummy treatment.
Diffuse Cutaneous Systemic SclerosisHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
This study is for people with advanced stomach or gut cancer that has a specific genetic marker called FGFR2b. It tests a new drug, bemarituzumab, combined with usual treatments (chemotherapy and nivolumab) to see if it works better than usual treatments alone.
Gastric and Gastroesophageal Junction Cancer With FGFR2b OverexpressionHungary - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
This study looks at a new drug, epcoritamab, combined with standard medicines (R2) for adults with follicular lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this new combination is.
Follicular Lymphoma (FL)Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, ZASOCITINIB (also called TAK-279), for people with moderate to severe plaque psoriasis. It compares the new medicine to existing treatments like Otezla and a dummy pill (placebo) to see how well it works and if it's safe.
Moderate to Severe Plaque PsoriasisHungary - Recruiting
Helping young people to adapt their internet use and promote mental well-being in a rapidly changing world
This study helps young people aged 12-16 learn healthier ways to use the internet and improve their mental well-being. It uses fun phone apps to teach skills for managing emotions and controlling internet habits, aiming to reduce potential harm from too much screen time.
Problematic usage of the internet in adolescentsHungary - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to investigate the safety, tolerability, and pharmacokinetics of Ent001 in patients with moderately to severely active ulcerative colitis
This study is looking at a new medicine called Ent001 for people in the UK with a bowel condition called ulcerative colitis. It wants to find out if the medicine is safe, how the body handles it, and if people can tolerate it well, especially if their colitis is quite active.
Inflammatory bowel disease (moderate to severe active ulcerative colitis)Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II A Pharmacokinetic Subtrial in Adolescent Patients with Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial
This study looks at how safe a medicine called KVD900 is when used long-term for swelling attacks in people with Hereditary Angioedema (HAE) Type 1 or 2. It also checks how the body handles the medicine in teenagers.
Hereditary Angioedema Type I or IIHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality
This study looks at a treatment called plasma exchange with human albumin for people with serious liver problems. We want to see if this treatment helps people live longer and get better, compared to standard care alone.
Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalizationHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR EXT)
This study looks at a medicine called Vericiguat for children with a type of heart failure. It checks how safe the medicine is and if it causes any unwanted effects. This is a follow-up study for those already taking part.
Heart Failure due to Systemic Left Ventricular Systolic DysfunctionHungary - Active not recruitingPHASE3
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is looking at how well two new drugs, enfortumab vedotin and pembrolizumab, work together to treat advanced bladder cancer that has spread. It compares them to standard chemotherapy treatments to see if they are a better option.
Urothelial CancerHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease
This study is testing different versions of an inhaler treatment for moderate to severe COPD. It wants to see if a new design works as well as the current one, and if both are better than using a dummy inhaler. We're looking at how well people can breathe.
Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease Long-term Safety With Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease.
This study looks at the long-term safety of a medicine called Entyvio for children and young people with Crohn's disease or ulcerative colitis. It aims to see how safe the treatment is over time and if it causes any side effects.
Ulcerative Colitis or Crohn's DiseaseHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-masked, placebo-controlled safety, tolerability, and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with chronic thyroid eye disease (TED)
This study is testing a new medicine, VRDN-001, for people with an eye condition called Thyroid Eye Disease (TED). Researchers want to see if it's safe, if it helps improve eye bulging and other symptoms, and how well people tolerate it.
Thyroid eye diseaseHungary - RecruitingPHASE3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).
Cardiovascular Disease and Lipoprotein(a)Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.
This study looks at a new combination medicine, CagriSema, for people with type 2 diabetes, kidney disease, and overweight or obesity. It compares CagriSema to existing treatments and a dummy medicine to see how it affects kidney health, weight, and blood sugar, while checking for side effects.
Chronic Kidney Disease, Type 2 diabetesHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
This study is comparing a new version of a rheumatoid arthritis medicine, called DRL_AB, with an existing one, Orencia. It aims to see if the new medicine works as well, is safe, and causes a similar immune response in people with moderate to severe rheumatoid arthritis.
Rheumatoid ArthritisHungary - Active not recruitingPHASE3
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
This study is looking at the long-term safety of a treatment called secukinumab for people with Polymyalgia Rheumatica (PMR). It's for those who have already been in a previous study for secukinumab and had their PMR symptoms come back after stopping treatment.
Polymyalgia RheumaticaHungary - RecruitingPhase III
Study evaluating the efficacy of icotrokinra in ulcerative colitis
This study is testing a new medicine, icotrokinra, for ulcerative colitis (UC) in adults and teenagers. It aims to see if icotrokinra can help reduce UC symptoms and keep the disease under control by targeting inflammation.
Ulcerative colitisHungary - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerHungary - Active not recruitingPHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study looks at new drug combinations for advanced lung cancer. It compares a new drug (Datopotamab Deruxtecan) with an existing treatment (Pembrolizumab) and chemotherapy, to see if the new combinations are safer and work better.
Metastatic Non Small Cell Lung CancerHungary - Active not recruitingPHASE2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study is testing a new medicine, Selinexor, for people in the UK with a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded to previous treatments. It aims to see if Selinexor can help when other options haven't worked.
Diffuse Large B-cell LymphomaHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
This study is looking at a new way to treat follicular lymphoma, a type of cancer. It compares a drug called Ibrutinib with a standard treatment, Rituximab. The aim is to see if adding Ibrutinib helps people live longer without their cancer getting worse.
Follicular LymphomaHungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.
Crohn’s disease, Ulcerative colitisHungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of heart failure where the heart struggles to pump blood effectively. It aims to see if different doses are safe and if the medicine helps improve heart health over 12 weeks.
Heart failure (HF) with reduced ejection fraction (HFrEF)Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
This study is testing a new treatment combination for locally advanced cervical cancer. It compares standard chemotherapy and radiation with the same treatment plus a new drug, pembrolizumab (Keytruda), to see if it helps patients live longer and stops the cancer from growing.
Locally Advanced Cervical CancerHungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of chronic heart failure. It aims to see if the medicine is safe and if it can improve how the heart works according to blood tests, compared to a dummy pill.
chronic heart failureHungary - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® Sourced from the European Union and United States in Healthy Male Participants
This study is looking at a new version of a medicine for bone conditions, called MAB-22. We want to see if it works the same way in the body as an existing medicine, Prolia®. Healthy men will take a single dose of one of these medicines.
Healthy volunteersHungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Hungary - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisHungary - Ongoing, recruitingTherapeutic use (Phase IV)
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST - Phase 4 – efficacy, A randomised, double-blind, controlled, parallel group, multi-centre trial
This study compares a flexible dose of Brodalumab, a psoriasis treatment, with its usual dose for people with moderate to severe plaque psoriasis who weigh 120 kg or more. It aims to see if the adjustable dose works better at clearing skin.
Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
This study is looking at a new way to treat AL amyloidosis, a rare condition where unhealthy proteins build up in your body. It compares a new drug called daratumumab with existing treatments to see if it works better and is safe for people newly diagnosed with the condition.
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)Hungary - AuthorisedTherapeutic exploratory (Phase II)
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
This study looks at a new type of cell therapy, called MB-CART2019.1, for people with a specific type of lymphoma that has come back or hasn't responded to other treatments. It checks how safe and effective it is.
Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)Hungary - Active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Urothelial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung CancerHepatocellular CarcinomaHungary - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Hungary - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerHungary - RecruitingPhase I/II
A two-part study to investigate the effects in adults of two doses of golexanolone in patients with primary biliary cholangitis with fatigue and cognitive dysfunction
This study looks at a new drug, golexanolone, for people with a liver condition called Primary Biliary Cholangitis (PBC) who also feel very tired and have trouble thinking clearly. Researchers want to see if it's safe, how it works in the body, and if it helps these symptoms.
Patients with primary biliary cholangitis with fatigue and cognitive dysfunctionHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
58-week Open-Label Trial of Tavapadon in Parkinson’s Disease (Tempo-4 Trial)
This study is looking at a new medication called Tavapadon for people with Parkinson's disease. Researchers want to see if it's safe and how well it helps with symptoms over 58 weeks. It's a Phase 3 trial, meaning it's a big step towards potentially becoming a new treatment.
Parkinson's diseaseHungary - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerHungary - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskHungary - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCHungary - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaHungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
This study is testing a new medicine, NNC0487-0111, for people with type 2 diabetes. It's looking at different ways to take the medicine (once a week shot or once a day pill) to see how safe and effective it is at controlling blood sugar.
Type 2 DiabetesHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy, Incorporating Extension Period - Continued Access for Venetoclax. (VIALE-A)
This study looks at a new treatment called venetoclax combined with an existing medicine called azacitidine for people with a type of blood cancer called Acute Myeloid Leukaemia (AML). It aims to see if this combination works better than azacitidine alone for patients who can't have standard strong chemotherapy.
Acute Myeloid LeukemiaHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
This study looks at a new medicine called batoclimab for Thyroid Eye Disease (TED). It’s for people who have already taken part in similar batoclimab studies. We want to see how long their eyes stay improved after stopping the medicine and if it helps those who didn't respond before.
Thyroid Eye Disease (TED)Hungary